GSK discount wins U.K. backing for Revolade; Lilly plots another $1.5B in stock buybacks;

@FiercePharma: A blow to Roche's Avastin hopes as NICE rejects it for Ovarian Cancer. Article | Follow @FiercePharma

> GlaxoSmithKline ($GSK) persuaded U.K. cost-effectiveness officials to back its Revolade blood drug by offering a discount. Report

> Eli Lilly ($LLY) directors approved a new $1.5 billion stock-buyback plan for 2013, on top of $3 billion in share repurchases over the past dozen years. Report

> Shire's ADHD drug Vyvanse won approval from U.K. gatekeepers, clearing the way for approval in 7 other countries that participated in a decentralized review of the drug under EU rules. Report

> Sun Pharmaceutical Industries snapped up the generics business of URL Pharma, a U.S. subsidiary of Takeda Phamaceuticals. Report

> Apotex and Aurobindo Pharma won FDA approval for their versions of the ViiV Healthcare HIV drug Ziagen. Report

Medical Device News

 @FierceMedDev: Quidel wins 510(k) for C. difficile molecular Dx. More | Follow @FierceMedDev

@MarkHFierce: More Dx funding--this time for Ortho Kinematics, a spine imaging Dx company--$2M Series B. Item | Follow @MarkHFierce

 @DamianFierce: Medtronic posts more good renal denervation data, but it faces mounting competition from $BSX, $STJ. Story | Follow @DamianFierce

> St. Jude Medical enrolls first patient in cardiac stent imaging guidance trial. Article

> GE licenses Alzheimer's imaging agent to Merck. Report

> Disgraced ex-Home Diagnostics head avoids jail time. News

Biotech News

 @FierceBiotech: Celgene wraps $500M deal to partner with Sutro on next-gen ADCs. Article | Follow @FierceBiotech

@JohnCFierce: Hey, Actelion is (kind of) on a roll, with positive psoriasis data on PhII drug. Handily beats placebo. Article | Follow @JohnCFierce

@RyanMFierce: Interesting how Merck is using GE's experimental imaging agent in Alzheimer's trial for MK-8931. Does this add risk? Report | Follow @RyanMFierce

> Vanda shares soar on positive PhIII data. Item

> Troubled drug developer Enzon looks for buyer as Icahn asks for chat. News

> Langer biotech adds $16M in venture cash to back next-gen cancer drugs. Story

Pharma Manufacturing News

> ICIG adds Tessenderlo plants to its portfolio. Report

> Teva puts brakes on $300M Philly warehouse. News

> FDA's counterfeit drug probe sweeps up cancer doc. Article

Biotech Research News

> Acetylon's HDAC drug fights sickle cell disease, beta thalassemia in blood cell studies. Item

> Lifting the mood: Antidepressant could double as diabetes drug. Report

> Engineered viruses rebuild heartbeat. Article

> Rejected diabetes drug wakes up cell memories in Alzheimer's. News

> Gene therapy flips switch in sickle cell disease. Story

And Finally... Why is Rudolph's nose red? Ask the BMJ. Report (sub. req.)

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.